[Alemtuzumab for multiple sclerosis]

Alva Diaz C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016000909
Spanish
Authors' recomendations: The evidence found on alemtuzumab for multiple sclerosis is scarce and of high quality. In direct comparisons, an increased effectiveness was observed for alemtuzumab versus interferon beta 1-alpha in decreasing relapses and disability increase in patients with relapsing-remitting multiple sclerosis, although with higher rates of significant adverse effects. There are no direct comparisons with other alternative drugs. The United States Food and Drug Administration, the European Drug Agency, different coverage policies and clinical practice guidelines approve and/or recommend its use for patients with highly active relapsing-remitting multiple sclerosis and/or highly refractory to other drugs. The Latin-American health sponsors do not cover it, being its high cost its main limitation for indication; its choice over other available options (fingolimod, teriflunomide, etc), will depend on the severity and the refractoriness, the presence of contraindications and the patient's preferences.
Details
Project Status: Completed
Year Published: 2016
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized
  • Multiple Sclerosis, Relapsing-Remitting
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.